NCT04910685 2026-03-10
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2/3 Recruiting
Clinical Trials
45 trialsNCT06915766 2026-03-09
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Cogent Biosciences, Inc.
Available
NCT05186753 2026-03-04
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cogent Biosciences, Inc.
Phase 2 Active not recruiting
NCT07255638 2026-02-10
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
Blueprint Medicines Corporation
Recruiting
NCT05362773 2026-01-13
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
Phase 1 Recruiting
NCT03731260 2025-09-23
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2 Active not recruiting
NCT00769587 2025-09-22
Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
Centre Hospitalier Universitaire, Amiens
Completed
NCT07142473 2025-08-26
MaRe
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT04996875 2025-05-30
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT00449748 2025-05-01
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03580655 2025-04-30
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2 Completed
NCT06065007 2025-04-04
Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis
Uppsala University
Active not recruiting
NCT03770273 2024-12-17
Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05219266 2024-06-28
Managed Access Programs for PKC412, Midostaurin
Novartis
No longer available
NCT04655118 2024-05-10
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
Telios Pharma, Inc.
Phase 2 Recruiting
NCT03401060 2024-05-03
DenosuMast
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT06210698 2024-01-18
Angioedema Biomarker Research Study
Foundation For Rare Disease Research
Unknown
NCT02571036 2023-12-13
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1 Completed
NCT06013683 2023-10-10
A Registry for Patients With Systemic Mastocytosis in China
The First Affiliated Hospital of Soochow University
Unknown
NCT05923372 2023-07-12
DALY-MAST
University Hospital, Toulouse
Unknown
NCT04333108 2023-05-06
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
AB Science
Phase 3 Unknown
NCT02561988 2023-03-17
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Blueprint Medicines Corporation
Phase 1 Completed
NCT03214666 2022-11-10
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
GT Biopharma, Inc.
Phase 1/2 Terminated
NCT00001756 2022-11-07
Study of Mast Cell Precursors
National Institutes of Health Clinical Center (CC)
Completed
NCT04695431 2022-01-10
Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
Blueprint Medicines Corporation
Completed
NCT00109707 2021-06-29
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
Novartis
Phase 1/2 Completed
NCT02620254 2021-02-04
Mast Cell Connect: A Registry for Patients With Mastocytosis
Blueprint Medicines Corporation
Completed
NCT01334996 2020-04-10
Use of Tamoxifen in Systemic Mastocytosis
Mayo Clinic
Completed
NCT00814073 2019-12-03
AB06006
AB Science
Phase 3 Completed
NCT03632811 2019-07-17
Mc_QoL
University Hospital, Toulouse
Completed
NCT02441166 2019-07-15
EvaTryMS
University Hospital, Toulouse
Phase NA Completed
NCT02808793 2019-03-13
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
Allakos Inc.
Phase 1 Completed
NCT01807598 2019-01-29
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Stanford University
Phase 2 Completed
NCT00782067 2018-11-15
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
Novartis
Phase 2 Completed
NCT02415608 2018-09-20
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
Stanford University
Phase 2 Terminated
NCT00171912 2017-02-23
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Novartis
Phase 2 Completed
NCT02380222 2017-01-10
Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
Adelphi Values LLC
Completed
NCT02478957 2016-09-29
Treatment of Indolent Systemic Mastocytosis With PA101
Patara Pharma
Phase 2 Completed
NCT01297777 2016-08-29
Imatinib in KIT-negative Systemic Mastocytosis
Hospital Virgen de la Salud
Phase 4 Completed
NCT01602939 2016-08-29
Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Hospital Virgen de la Salud
Phase 2/3 Unknown
NCT01920204 2015-01-19
Midostaurin in Indolent Systemic Mastocytosis
University Medical Center Groningen
Phase 2 Unknown
NCT00493129 2012-02-08
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00918931 2011-11-04
Obatoclax for Systemic Mastocytosis
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00979160 2009-09-18
Evaluation of Response of Dasatinib to Treat Mastocytosis
Federico II University
Phase 2 Unknown
NCT00001760 2007-12-13
Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals
National Institutes of Health Clinical Center (CC)
Completed